Srivani Konduri1, Roderich E Schwarz. 1. Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Division of Surgical Oncology, The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Abstract
BACKGROUND: Reports on hormone receptor expression of pancreatic cancer (PaCa) cells and treatment responses to antihormonal therapy are conflicting. We examined estrogen receptor (ER) expression in PaCa cells and investigated its function in estrogen-mediated cell proliferation. METHODS: Protein levels of ERalpha and ERbeta in 8 human PaCa lines were detected by Western blot analysis. Cell proliferation was measured by sulforhodamine B analysis. ER modulators included diethylstilbestrol (DES), estradiol (E2), 4-hydroxytamoxifen (Tam), genistein (Gen), and Coumestrol (Coum). RESULTS: ERalpha levels were detected in all eight, and ERbeta in seven cell lines. ERbeta/ERalpha ratio ranged from 0.4 to 111 (median: 6.4, >5 in seven lines). Median maximal growth stimulation (in %, observed at 20 to 200 nM) was 19 (DES), 39 (E2), 20 (Tam), 22 (Gen), and -9 (Coum); median maximal inhibition (at 40 to 60 microM) was 59 (DES), 36 (E2), 25 (Tam), 43 (Gen), and 50 (Coum). The extent of E2 and Gen stimulatory effects correlated with the ERbeta/ERalpha ratio (Kendall's tau: 0.714, P = 0.024), but not ERalpha or ERbeta levels alone. Only Coum-induced inhibition correlated with the ERbeta/ERalpha ratio (P = 0.006) and with ERalpha expression (r = 0.753, P = 0.03). Gemcitabine-induced PaCa cytotoxicity (at IC(40)) was significantly reduced by E2, Gen, and Coum. CONCLUSIONS: PaCa proliferation in vitro is highly estrogen sensitive, and in contrast to other reports, ERs are frequently expressed. In 7/8 cell lines, ERbeta expression outweighs ERalpha expression. The impact of the ERbeta/ERalpha ratio on estrogen-mediated growth stimulation and reduced cytotoxicity at physiological concentrations may have clinical implications on PaCa therapy.
BACKGROUND: Reports on hormone receptor expression of pancreatic cancer (PaCa) cells and treatment responses to antihormonal therapy are conflicting. We examined estrogen receptor (ER) expression in PaCa cells and investigated its function in estrogen-mediated cell proliferation. METHODS: Protein levels of ERalpha and ERbeta in 8 human PaCa lines were detected by Western blot analysis. Cell proliferation was measured by sulforhodamine B analysis. ER modulators included diethylstilbestrol (DES), estradiol (E2), 4-hydroxytamoxifen (Tam), genistein (Gen), and Coumestrol (Coum). RESULTS:ERalpha levels were detected in all eight, and ERbeta in seven cell lines. ERbeta/ERalpha ratio ranged from 0.4 to 111 (median: 6.4, >5 in seven lines). Median maximal growth stimulation (in %, observed at 20 to 200 nM) was 19 (DES), 39 (E2), 20 (Tam), 22 (Gen), and -9 (Coum); median maximal inhibition (at 40 to 60 microM) was 59 (DES), 36 (E2), 25 (Tam), 43 (Gen), and 50 (Coum). The extent of E2 and Gen stimulatory effects correlated with the ERbeta/ERalpha ratio (Kendall's tau: 0.714, P = 0.024), but not ERalpha or ERbeta levels alone. Only Coum-induced inhibition correlated with the ERbeta/ERalpha ratio (P = 0.006) and with ERalpha expression (r = 0.753, P = 0.03). Gemcitabine-induced PaCa cytotoxicity (at IC(40)) was significantly reduced by E2, Gen, and Coum. CONCLUSIONS: PaCa proliferation in vitro is highly estrogen sensitive, and in contrast to other reports, ERs are frequently expressed. In 7/8 cell lines, ERbeta expression outweighs ERalpha expression. The impact of the ERbeta/ERalpha ratio on estrogen-mediated growth stimulation and reduced cytotoxicity at physiological concentrations may have clinical implications on PaCa therapy.
Authors: L K Marriott; K R McGann-Gramling; B Hauss-Wegrzyniak; L C Sheldahl; R A Shapiro; D M Dorsa; G L Wenk Journal: Endocrine Date: 2008-02-05 Impact factor: 3.633
Authors: Michelle Kim; Perri Deacon; Rommel G Tirona; Richard B Kim; Christopher L Pin; Henriette E Meyer Zu Schwabedissen; Rennian Wang; Ute I Schwarz Journal: Histochem Cell Biol Date: 2017-05-10 Impact factor: 4.304
Authors: Ioannis Pozios; Thomas Knösel; Yue Zhao; Gerald Assmann; Iraklis Pozios; Mario H Müller; Christiane J Bruns; Martin E Kreis; Hendrik Seeliger Journal: J Cancer Res Clin Oncol Date: 2018-07-25 Impact factor: 4.553
Authors: Aleksandra Fucic; Marija Gamulin; Zeljko Ferencic; Jelena Katic; Martin Krayer von Krauss; Alena Bartonova; Domenico F Merlo Journal: Environ Health Date: 2012-06-28 Impact factor: 5.984
Authors: Barbara D Boyan; David A Hart; Roger M Enoka; Daniel P Nicolella; Eileen Resnick; Karen J Berkley; Kathleen A Sluka; C Kent Kwoh; Laura L Tosi; Mary I O'Connor; Richard D Coutts; Wendy M Kohrt Journal: Biol Sex Differ Date: 2013-02-04 Impact factor: 5.027
Authors: L F Grochola; T Greither; H Taubert; P Möller; U Knippschild; A Udelnow; D Henne-Bruns; P Würl Journal: Br J Cancer Date: 2008-09-09 Impact factor: 7.640
Authors: Hendrik Seeliger; Ioannis Pozios; Gerald Assmann; Yue Zhao; Mario H Müller; Thomas Knösel; Martin E Kreis; Christiane J Bruns Journal: BMC Cancer Date: 2018-10-29 Impact factor: 4.430